title: Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy.
abstract: The present study was undertaken to determine the effects of etidronate (ED) on calcitriol-induced aortic calcification and bone metabolism in rats with renal failure. Severe aortic calcification was induced by treatment with calcitriol for 3 weeks in rats in which 5/6 of the kidneys were removed (SNx group). Treatment of ED (10 mg/kg) together with calcitriol after subtotal nephrectomy (SNx) significantly inhibited thoracic and abdominal aortic calcification 3 weeks after the operation; however, ED (2 mg/kg) was ineffective. The serum levels of osteocalcin and pyridinoline decreased in ED (10 mg/kg) treated-renal failure rats compared with SNx rats. Total bone mineral density (BMD) in the SNx group was lower than that in the sham group, in which animals were treated with calcitriol after a sham operation. The total BMD value in the ED (10 mg/kg)-treated group was similar to that in the SNx group, whereas the levels of cancellous BMD were low in the ED (10 mg/kg)-treated rats. Our data show that ED at a dosage that suppresses bone metabolism markedly inhibits vascular calcification in rats with renal failure.
authors.affiliation: Department of Endocrine Pharmacology, Tokyo University of Pharmacy & Life Science, Gunma, Japan. hiro@ps.toyaku.ac.jp
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Tamura
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Hirotake
authors.initials: H
authors.lastname: Hashiba
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamura
authors.forename: Sumio
authors.initials: S
authors.lastname: Aizawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kogo
mesh_terms: D000596:Amino Acids / Q000097:blood; D000818:Animals; D001012:Aorta, Abdominal; D001013:Aorta, Thoracic; D001018:Aortic Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D001835:Body Weight; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002114:Calcinosis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D002117:Calcitriol; D002120:Calcium Channel Agonists / Q000494:pharmacology; D003404:Creatinine / Q000097:blood; D004195:Disease Models, Animal; D004347:Drug Interactions; D012968:Etidronic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009392:Nephrectomy; D015675:Osteocalcin / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
chemical_list: D000596:Amino Acids; D002120:Calcium Channel Agonists; D015675:Osteocalcin; C015484:pyridinoline; D003404:Creatinine; D002117:Calcitriol; D012968:Etidronic Acid